- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Exhaled Carbon Monoxide Levels Associated With Lower Risk of Parkinson’s disease: JAMA

A large-scale nationwide prospective cohort study analyzing over half a million adults within the China Kadoorie Biobank has provided critical mechanistic insights into neuro-epidemiological patterns. The study concluded that among individuals who never smoked, higher exhaled carbon monoxide (CO) levels were associated with lower Parkinson disease (PD) risk, demonstrating a potentially protective role of CO in PD etiology, which helps explain the inverse association between smoking and PD and supports ongoing clinical trials of CO in PD treatment. The study was published in JAMA Neurology by Clara B. and colleagues.
For the assessment of any prospective relationship between exhaled CO concentrations and risk of PD, researchers used data from the China Kadoorie Biobank study. Data was collected from 512,724 adults aged between 30 and 79 years who belonged to 10 geographically diverse regional areas of China during June 2004 and July 2008. The prospective analysis involved 512,701 individuals with information of their first disease occurrence within the age range of 40 to 94 years before January 1, 2019, where data analysis was done between May 2025 and March 2026.
Self-reported smoking status and baseline exhaled CO concentration in ppm were measured among the risk factors. There was a total number of 1,131 new occurrences of Parkinson disease and 2,949 occurrences of other neurodegenerative diseases in an average follow-up period of 12 years using national death and disease registries and health insurance records. Cox proportional hazard regression models were developed for sociodemographic characteristics, lifestyle, solid fuel combustion, and second-hand smoke exposure to estimate adjusted HRs.
Key findings:
- Longitudinal assessment in 512,701 analyzed subjects (mean age 52 ± 11 years; 302,041 women [58.9%]; 156,650 men [74.5%] and 9,944 women [3.3%] ever regular smokers) confirmed robust dose-dependent protective effects.
- Mean levels of exhaled carbon monoxide were significantly higher in regular smokers (11.1 ppm) than in never-smokers (3.5 ppm), occasional smokers (3.8 ppm) and former regular smokers (3.7 ppm).
- Regular smoking was associated with reduced PD risk (adjusted HR, 0.70; 95% CI, 0.62–0.79).
- In the subset of 675 never-smokers with PD, higher exhaled CO levels showed a significant dose-dependent inverse correlation with disease incidence (< 2.0 ppm: 1.00 [95% CI, 0.85–1.18]; 2.0 to < 3.0 ppm: 0.85 [95% CI, 0.73–0.99]; 3.0 to < 5.0 ppm: 0.62 [95% CI, 0.53–0.73]; 5.0 to < 11.5 ppm: 0.68 [95% CI, 0.56–0.83]; ≥11.5 ppm: 0.65 [95% CI, 0.45–0.92]; P for trend < 0.001).
- Higher exhaled CO in never-smokers was not associated with an increased risk of vascular diseases caused by traditional smoking and other neurodegenerative disorders except PD. Protective effects were more evident in female never-smokers.
Overall, it is shown that elevated exhaled carbon monoxide levels are related to the decreased incidence of PD, in a dose-response relationship, amongst non-smokers in population data from the China Kadoorie Biobank. In addition, the findings of this study clearly show that carbon monoxide has a biological protective effect on the cause of Parkinson disease, which explains why previous findings have found smoking to be linked to decreased Parkinson disease incidence.
Reference:
Bueno Lopez C, Iona A, Turnbull I, et al. Smoking, Exhaled Carbon Monoxide, and Risk of Parkinson Disease. JAMA Neurol. 2026;83(11):1045–1056. doi:10.1001/jamaneurol.2026.3037
Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

